AJCC第8版分期对黑色素瘤分期与生存的影响
研究纳入1948例II-IV期皮肤黑色素瘤患者,按AJCC第7版与第8版分别分期。23.5%患者亚组改变,主要为IIIC期上移;两版预测准确性相当。AJCC8 IIB/IIC期5年黑色素瘤特异性生存低于IIIA期。
要点
- AJCC8导致23.5%患者亚组改变,主要为IIIC期上移。
- AJCC8 IIB/IIC期5年MSS为80%和67%,低于IIIA期的89%。
- AJCC8与AJCC7预测准确性相当(AUC 0.74 vs 0.75)。
核心结论
- AJCC8主要影响III期亚组,II期影响较小。
- AJCC8 IIB/IIC期患者5年MSS为67-80%,应考虑辅助治疗。
- IIIA期辅助治疗指征存疑。
研究设计与样本
- 多中心回顾性队列研究,纳入两个三级皮肤癌中心的1948例≥18岁II-IV期皮肤黑色素瘤患者。
- 按AJCC7和AJCC8分别分期,采用log二项模型评估性别和年龄对再分期的影响。
- 使用逆概率删失加权法从生存时间数据计算ROC曲线,比较两版判别能力。
- 计算黑色素瘤特异性生存和总生存,使用Cox比例风险模型估计年龄和性别调整的MSS风险比。
主要发现
- 23.5%的患者按AJCC8被分配到不同亚组。
- IIIC期比例从AJCC7的24.8%上升至AJCC8的50.8%。
- IIIA期比例从28.7%降至16.2%,IIIB期从46.5%降至28.3%。
- AJCC7和AJCC8的预测准确性相当,整合时间依赖AUC分别为0.75和0.74。
- AJCC8 IIB、IIC和IIIA期的5年MSS分别为80%、67%和89%。
关键数值与推荐
- AJCC8 IIB期5年MSS为80%。
- AJCC8 IIC期5年MSS为67%。
- AJCC8 IIIA期5年MSS为89%。
- AJCC7与AJCC8整合时间依赖AUC分别为0.75和0.74。
临床怎么用
- AJCC8 IIB/IIC期患者5年MSS较低,应考虑辅助治疗。
- AJCC8 IIIA期辅助治疗指征需谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The American Joint Committee on Cancer (AJCC) 8th staging system introduced several revisions. To assess the impact of the 8th edition American Joint Committee on Cancer (AJCC8) staging system on subgrouping and survival, patients with melanoma from two tertiary skin cancer centres were classified according to both the 7th edition American Joint Committee on Cancer (AJCC7) and AJCC8. METHODS: A total of 1948 patients aged ≥18 years with cutaneous melanoma stage II-IV were included. The impact of sex and age on reclassification was assessed by log binomial models. The inverse probability of censoring weighting method was used to compute ROC curves from time-to-event data to assess the discriminatory ability of AJCC7 and AJCC8. Melanoma-specific survival (MSS) and overall survival (OS) were calculated, and age- and sex-adjusted MSS hazard ratios were estimated using Cox proportional hazards models. RESULTS: Of all, 23.5% of patients were assigned a different subgroup when classified according to AJCC8. Owing to upshifting to stage IIIC (AJCC7 24.8% vs. AJCC8 50.8%), patient numbers of stages IIIA and IIIB decreased from 28.7% to 16.2% and 46.5% to 28.3%. The prediction accuracy for AJCC7 and AJCC8 was comparable (integrated time-dependent area under the curve [AUC] of 0.75 and 0.74, respectively). Five-year MSS of IIB and IIC AJCC8 was poor and lower than that of IIIA AJCC8 (80%, 67% and 89%, respectively). Compared to results of the International Melanoma Database and Discovery Platform, 5-year MSS was 10-15% points lower for stages IIC, IIIB and IIIC. CONCLUSIONS: Upshifting affects primarily stage III subgroups, while effects in stage II are minor. Stage IIB/C (AJCC8) patients have 67-80% MSS and should be considered for adjuvant treatment, while in stage IIIA, the indication of adjuvant treatment is questionable.
引用
- Kanaki T, Stang A, Gutzmer R, et al. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. Eur J Cancer. 2019. PMID: 31401470. doi:10.1016/j.ejca.2019.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。